Back Pain News and Research

Latest Back Pain News and Research

Flowonix Medical's new Patient Therapy Controller approved for market release

Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.

7 Aug 2015

Pennsylvania physicians examine back-to-school health, offer tips for parents and students

As students start heading back to classes for the upcoming academic year, Pennsylvania physicians take a close look at back-to-school health and offer some tips for parents and students who strive to stay in class and not home in bed sick.

7 Aug 2015

In vitro testing provides proof of concept for osteopathic manipulative therapy

In vitro studies of the cellular effects of modeled osteopathic manipulative therapy (OMT) provide proof of concept for the manual techniques practiced by doctors of osteopathic medicine (DOs), according to researchers from the University of Arizona College of Medicine - Phoenix.

5 Aug 2015

Special issue of Ergonomics in Design explores health and safety effects of sedentary workplace

Recent research has shown that the more time employees spend in their chairs, the more likely they are to develop serious health problems such as diabetes, heart disease, and obesity. The July special issue of Ergonomics in Design examines the health and safety effects of the sedentary workplace, the pros and cons of alternatives to sitting at work (for example, sit-stand and treadmill workstations, ball chairs), and proposed workplace design solutions.

4 Aug 2015

Researchers design new driver seat that can be adjusted using simple hand gestures

A multitude of professional drivers suffer from back problems. One cause: driver seats that are inadequately adjusted to each driver's ergonomic needs.

3 Aug 2015

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.

30 Jul 2015

Better pain relief options for individuals with chronic back and leg pain

Chronic back and leg pain sufferers in search of better pain relief options may have a new choice. According to a study published in the Online First edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, patients who received a novel high frequency form of spinal cord stimulation (SCS) therapy experienced significantly greater, long-term relief for both chronic back and leg pain, when compared to a traditional low frequency form of SCS therapy.

29 Jul 2015

Doctors of chiropractic points out dangers of heavy backpacks

As students savor the last precious weeks of summer vacation, parents are out making the final run for school supplies. So, parents, take note: When back-to-school shopping this year there is one essential item that requires very special attention: your child's backpack.

25 Jul 2015

Prolonged standing in workplace may lead to serious health consequences

Recent research has warned of the health detriments associated with sitting for long stretches of time at the office, but what about the nearly half of all employees worldwide who are required to stand for more than 75% of their workdays? Prolonged standing is associated with short-term adverse health issues, including reports of fatigue, leg cramps, and backaches, which can affect job performance and cause significant discomfort.

15 Jul 2015

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint.

9 Jul 2015

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents.

8 Jul 2015

Study: Osteopathic manipulative therapy decreases low back pain by over 70% in postpartum women

German researchers found osteopathic manipulative therapy (OMTh) decreased postpartum low back pain by over 70 percent in women who had given birth at least three months before beginning treatment, according to a new study published in July issue of the Journal of the American Osteopathic Association.

1 Jul 2015

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States.

30 Jun 2015

ProfNet network experts available to discuss timely issues in your coverage area

Below are experts from the ProfNet network that are available to discuss timely issues in your coverage area. You can also submit a query to the hundreds of thousands of experts in our network – it's easy and free!

27 Jun 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

New form of talking therapy shows promise for people suffering from chronic low back pain

New research from Royal Holloway, University of London has found that a new form of talking therapy is a credible and promising treatment for people with chronic low back pain who are also suffering from related psychological stress.

17 Jun 2015

Men's poor health costs $36.9 billion a year for Canada

Canadian Men's Health Week is kicking off with an urgent message: Unhealthy lifestyle choices are running rampant, and they are costing this country an arm and a leg.

15 Jun 2015

NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) show that diclofenac, naproxen and etoricoxib significantly inhibit ovulation in women with mild musculoskeletal pain. Of the women receiving NSAIDs, only 6.3 percent (diclofenac), 25 percent (naproxen) and 27.3 percent (etoricoxib) ovulated, compared with 100 percent of the control group.

12 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

Back Pain News and Research

Latest Back Pain News and Research

Flowonix Medical's new Patient Therapy Controller approved for market release

Pennsylvania physicians examine back-to-school health, offer tips for parents and students

In vitro testing provides proof of concept for osteopathic manipulative therapy

Special issue of Ergonomics in Design explores health and safety effects of sedentary workplace

Researchers design new driver seat that can be adjusted using simple hand gestures

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Better pain relief options for individuals with chronic back and leg pain

Doctors of chiropractic points out dangers of heavy backpacks

Prolonged standing in workplace may lead to serious health consequences

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Study: Osteopathic manipulative therapy decreases low back pain by over 70% in postpartum women

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

ProfNet network experts available to discuss timely issues in your coverage area

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

New form of talking therapy shows promise for people suffering from chronic low back pain

Men's poor health costs $36.9 billion a year for Canada

NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Back Pain News and Research

Latest Back Pain News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in